uftoral has been researched along with Carcinoma, Non-Small Cell Lung in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (47.83) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aerts, JG; Gras, J; Hoogsteden, H; Pouw, E; Pronk, T; Salomé, J; Schmitz, PI; Surmont, V; Tan, KY; van Klaveren, RJ; Vernhout, R | 1 |
| Fukushima, M; Tanaka, F; Wada, H | 1 |
| Fukushimab, M; Matsuoka, K; Miyahara, R; Nakagawa, T; Otake, Y; Takata, T; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Asoh, H; Fukuyama, Y; Ichinose, Y; Ikeda, J; Teruya, T; Ushijima, C; Yamaguchi, M | 1 |
| Hanaoka, N; Tanaka, F; Wada, H | 1 |
| Hidaka, H; Koga, T; Nomiyama, H; Yano, T | 1 |
| Miyahara, R; Otake, Y; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Fukushima, M; Ishikawa, S; Miyahara, R; Nakagawa, T; Tanaka, F; Wada, H | 1 |
| Ichinose, Y; Okamoto, T | 2 |
| Tanaka, F; Wada, H | 1 |
| Fujita, H; Fujita, K; Fukuda, Y; Fukushima, M; Ishioka, T; Ito, H; Kishibe, S; Kogawa, R; Koie, H; Kudo, T; Machida, S; Maruyama, A; Sato, T; Takashima, K; Tsuge, T; Tsushima, T; Yagihashi, N | 1 |
| Kobayashi, K | 1 |
| Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P | 1 |
| Hitomi, S; Otake, Y; Tanaka, F; Wada, H | 1 |
| Hitomi, S; Tanaka, F; Wada, H | 1 |
| Ichinose, Y; Kuba, M; Kudoh, S; Morikawa, T; Niitani, H; Yano, T; Yoshimori, K | 1 |
| Koinumaru, S; Matsuda, T; Nakai, Y; Saitoh, J | 1 |
| Taguchi, T | 1 |
| Fukuse, T; Hitomi, S; Miyahara, R; Ohtake, Y; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Benner, SE; Canetta, R; Hoff, PM; Pazdur, R | 1 |
| Langer, CJ | 2 |
11 review(s) available for uftoral and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
UFT and S-1 for treatment of primary lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Lung Neoplasms; Oxonic Acid; Radiotherapy, Adjuvant; Tegafur; Time Factors; Treatment Outcome; Uracil | 2010 |
Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Life Tables; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neovascularization, Pathologic; Pneumonectomy; Postoperative Period; Prodrugs; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Uracil; Vascular Endothelial Growth Factor A | 2004 |
[Postoperative adjuvant chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Pneumonectomy; Postoperative Care; Randomized Controlled Trials as Topic; Tegafur; Uracil; Vinblastine; Vindesine; Vinorelbine | 2005 |
[Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Evidence-Based Medicine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Pneumonectomy; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2006 |
[Adjuvant chemotherapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Lung Neoplasms; Meta-Analysis as Topic; Pneumonectomy; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Uracil; Vinblastine; Vinorelbine | 2006 |
[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Fluorouracil; Humans; Lung Neoplasms; Tegafur; Uracil | 1996 |
[Adjuvant chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Tegafur; Uracil; Vindesine | 1997 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Combinations; Fluorouracil; Humans; Lung Neoplasms; Neoplasms; Tegafur; Uracil | 1997 |
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Combinations; Humans; Leucovorin; Lung Neoplasms; Neoplasms; Stomach Neoplasms; Tegafur; Uracil | 1998 |
The role of tegafur/uracil in pulmonary malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Drug Combinations; Drug Synergism; Humans; Lung Neoplasms; Tegafur; Uracil | 1999 |
The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Combinations; Humans; Leucovorin; Lung Neoplasms; Tegafur; Treatment Outcome; Uracil | 2001 |
6 trial(s) available for uftoral and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
Topics: Administration, Oral; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leucovorin; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Tegafur; Uracil | 2009 |
[A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Picibanil; Prospective Studies; Survival Rate; Tegafur; Uracil; Vindesine | 1996 |
Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Head and Neck Neoplasms; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 1997 |
Postoperative adjuvant chemotherapy for non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. The Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Humans; Japan; Lung Neoplasms; Multivariate Analysis; Postoperative Care; Prognosis; Survival Rate; Tegafur; Uracil | 1997 |
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Combinations; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Tegafur; Thrombocytopenia; Uracil; Vomiting | 1997 |
Pilot study of UFT combined with 5 consecutive days cisplatin in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Pilot Projects; Tegafur; Uracil | 1997 |
6 other study(ies) available for uftoral and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxidoreductases; Postoperative Care; Prognosis; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
[A case of preoperative concurrent chemoradiotherapy and curative resection for locally advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Combinations; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Preoperative Care; Tegafur; Uracil | 2002 |
Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Tumor Suppressor Protein p53; Uracil | 2002 |
[UFT plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer--its application to outpatient practice].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Radiotherapy Dosage; Survival Rate; Tegafur; Uracil | 2003 |
UFT inhibits lung metastases in spontaneous metastasis model of lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Humans; Hydroxybutyrates; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Tegafur; Uracil | 2005 |
Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Uracil | 1998 |